You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
23 April 2026 - Finnish pharmaceutical company Orion Corporation (Orion Pharma) (HEL:ORNBV) said on Thursday that it has initiated the TEADCO Phase 1b/2 basket trial evaluating ODM-212, an oral pan-TEAD inhibitor, in combination with standard-of-care...
23 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced late Wednesday that the US Food and Drug Administration has approved Dupixent (...
23 April 2026 - Thryv Therapeutics Inc, a Canada-based, clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, ...
23 April 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Thursday that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), ...
23 April 2026 - US laboratory services provider Labcorp (NYSE:LH) announced on Wednesday the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the US Food and Drug Administration (...
22 April 2026 - Biotherapeutics company PureTech Health plc reported on Wednesday that its founded entity Gallop Oncology reported positive topline Phase 1b data for LYT-200 in relapsed/refractory high-risk myelodysplastic syndrome (MDS) and acute my...